Healthcare
Live Price
Offline$1.88
+5.62% today
1Y Change
-13.74%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stereotaxis, Inc. (STXS) is a Healthcare stock with a market cap of $190.00M and listed on AMEX. The stock last traded around $1.88 and down 13.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +20.3%, EPS growth of +16.7%, a dividend yield of 0.0%. What stands out right now is revenue +20.3%, EPS +16.7%, free cash flow -61.5% with operating margin -68.3% and ROIC -72.4%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines STXS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STXS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STXS Max Drawdown
-51.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STXS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$35.0M
+24.4% YoY
FY Net Income
-$10.7M
+41.4% YoY
Free Cash Flow
-$4.3M
+59.8% YoY
Revenue Growth
+20.3%
EPS Growth
+16.7%
Gross Margin
52.7%
Net Margin
-66.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 32M | 27M | 27M | 28M | 35M |
| Gross Profit | 17M | 15M | 15M | 18M | 23M |
| Operating Income | -22M | -25M | -22M | -19M | -13M |
| EBITDA | -21M | -24M | -21M | -18M | -13M |
| Net Income | -22M | -24M | -21M | -18M | -11M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13M | 12M | 20M | 9M | 39M |
| Total Assets | 52M | 47M | 42M | 53M | 61M |
| Total Liabilities | 34M | 35M | 20M | 21M | 22M |
| Shareholder Equity | 19M | 11M | 22M | 32M | 39M |
| Total Debt | 5M | 6M | 5M | 6M | 6M |
| Net Debt | -8M | -6M | -14M | -3M | -33M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+65.0% YoY
Capital Expenditures
1M
+41.3% YoY
Free Cash Flow
4M
+59.8% YoY
Key ratios
Gross Margin
52.7%
Operating Margin
-68.3%
Net Margin
-66.8%
ROE
-191.6%
Debt / Equity
0.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.